I
n a setting of rapidly increasing health care costs, the ability to compare the relative value of interventions is crucial to inform clinical decisions about the use of alternate interventions and coverage decisions. Cost-effectiveness analyses that report a cost per quality-adjusted-life-year (QALY) outcome measure are widely used for this purpose, 1 and a growing number of prospective randomized clinical trials include economic end points. Analysts conducting a cost-effectiveness analysis can either use off-theshelf utility weights available from existing catalogs [2] [3] [4] or collect primary data from the patient population enrolled in the trial. The most common method for assessing preferences in clinical settings is using one of the prescored multiattribute health state classification systems such as the EuroQol-5D (EQ-5D) or the Health Utility Index Mark 3 (HUI3). 5 The use of these instruments should be able to capture changes in a patient's quality of life related to the treatment under study, and should be also able to discriminate among groups and determine differences by patients' disease severity.
In this issue of Medical Decision Making, Winkelmayer and others report results from a health utility assessment in a large patient population at cardiovascular risk, and focus on the need to assess health state utilities in elderly patients. 6 The underlying premise is that utility estimates that are available from the literature and published catalogs were derived from nonelderly populations and hence are not generalizable to elderly individuals. 7 Winkelmeyer and others claim that "it is possible that elderly individuals hold a different preference regarding a specific health state compared to younger persons, specifically in the presence of several other chronic conditions" (p. 248). They administered the HUI3 to all PROSPER trial participants to estimate directly each patient's health state at time of interview. They then used the scale's multiattribute utility function to estimate the resulting utilities. Here we identify a problem that the authors were indeed aware of. The HUI instrument and the associated multiattribute utility function were derived from a considerably younger population. This brings us back to square one. Their study was targeted to avoid using data derived from younger populations and ended up using exactly such community-derived data! All the relative advantage gained by administering a generic health state classification system directly to the study population may be lost by using transformations derived from a generic younger population.
The authors state that "such an economic evaluation would not be influenced by the quality of those life years saved, but predominantly by effectiveness demonstrated in the differences in life years saved" (p. 253). However, results from PROSPER show that although treatment with a statin (Pravastatin) significantly reduced the incidence of the primary endpoint in the trial (a composite end point of coronary heart disease death or nonfatal myocardial infarction or fatal or nonfatal stroke), there was no observed difference in all-cause mortality between treatment arms. 8 Although the economic analysis conducted alongside the PROSPER trial has not been published yet, the average number of life years gained for a patient enrolled in the active treatment arm is likely to be very small. Moreover, even if more significant mortality differences were detected
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in the trial, the number of life-years gained would have been bounded by the advanced age (mean age = 75 years) of the study population and the limited life expectancy in the first place. The lack of mortality effect in the trial emphasizes the importance of a valid utility measurement, and the economic merit of the study drug in elderly patients is mainly dependent on differences in patients' quality of life. The lack of a difference in HUI3 utilities among health states with regard to myocardial infarction and the lack of discrimination among the groups may have important implications on results of a cost-effectiveness analysis. It is possible that HUI3 and other generic instruments are not sensitive enough to detect small changes in patients' related quality of life. These findings are crucial for assessing the cost-effectiveness of many other interventions in medicine, which are primarily designed to address patients' quality of life rather than longevity. Using disease-specific quality-of-life instruments may provide additional supportive data for the assessment of efficacy for such interventions.
Several other potential problems may arise from using preference-weighted health classification systems for economic evaluations. First, these systems differ considerably in terms of the dimensions of health they cover, items and preference weights, and in the instrument used to determine the preferencebased scoring. Thus, it is not surprising that comparative studies, in various health conditions, show that the same patient groups can score quite differently depending upon the instrument used. [9] [10] [11] The PROSPER researchers used the HUI3 for assessing utilities and found no differences in utilities associated with 3 myocardial infarction states. It is possible that other instruments would have been more responsive to the changes expected in the study patients and would result in higher or lower utility scores for the same morbid condition.
Another issue that is sometimes raised in instrument selection is the fact that each instrument is scored based on preferences from a particular population and those preferences may not apply to other populations. Although the preferences for the HUI3 were measured on a random sample of general population adults living in the city of Hamilton, Canada, 12 the PROSPER study was conducted in Scotland, Ireland, and the Netherlands. However, findings from several studies suggest that when preference measurement procedures are replicated on different groups of people (including race, income, and gender) and different populations in different countries, the results are similar. 13 The HUI3 allows respondents to answer "don't know" to any given question, for which there is no scoring instruction. Indeed, more than a quarter of the PROSPER study gave either a don't know answer or refused to answer at least one question, which precluded calculations of utility weights for these participants. It turned out that age was an important factor in invalid responses. Elimination of these responses raises the question of whether the remaining data can be used for the more elderly population (where many responses were invalid). Recently, methods for handling missing data in the HUI3 have been tested and should be considered in future studies. 14 The article by Winkelmayer and others has important contributions to the literature. It is one of the largest attempts to estimate health utilities in an elderly population at cardiovascular risk and addresses the impact of demographic and clinical characteristics on these utility weights. More broadly, this study calls for further research to validate health utility elicitation methods in the elderly and implies that their results cannot be generalized to other populations. Although primary data collection of utility weights may be preferable, this may not be feasible due to the time or expense involved. When using utility weights from previous studies, analysts conducting costeffectiveness research should pay special attention to the source of these estimates as well as the instrument used. Sensitivity analyses with varying utility values should always be used to determine their potential impact on cost-effectiveness results.
